Quick Summary
- Can-Fite BioPharma achieved its Phase 2a primary safety objective for namodenoson in patients with advanced pancreatic cancer, with no unexpected adverse events reported.
- Twenty heavily pretreated patients with advanced pancreatic ductal adenocarcinoma (PDAC) participated in the clinical study.
- Approximately one-third of study participants remained alive when the data was analyzed, with continued survival monitoring underway.
- The FDA has awarded namodenoson Orphan Drug Designation for treating pancreatic cancer.
- The company plans to share findings at upcoming medical conferences, with additional survival data expected later.
On March 4, 2026, Can-Fite BioPharma announced successful Phase 2a safety outcomes for namodenoson in patients battling advanced pancreatic cancer. The treatment demonstrated good tolerability across 20 previously treated patients, with no unexpected safety concerns emerging. Approximately 33% of trial participants were still living when data was collected, and researchers continue to track survival outcomes.
Namodenoson functions as a selective A3 adenosine receptor agonist. Its mechanism involves targeting receptors that show elevated expression levels in cancer and inflammatory cells compared to healthy tissue. The company has pursued development of this compound across various cancer indications, with liver cancer being another key focus area.
This pancreatic cancer investigation utilized an open-label design and recruited participants who had previously experienced treatment failure with standard systemic therapies. These patients represent an especially challenging population to treat. Pancreatic cancer ranks among the deadliest malignancies, and individuals who have run out of standard treatment alternatives face severely limited options.
The trial’s 20 participants presented with varied medical backgrounds, and many suffered from metastatic disease. Several had undergone two or more previous treatment regimens, classifying them as a particularly high-risk patient population.
Safety served as the study’s primary endpoint, which namodenoson successfully met. Secondary measures included overall survival duration and progression-free survival, with these data points still developing.
FDA Orphan Drug Recognition
Namedenoson has received Orphan Drug Designation from the FDA specifically for pancreatic cancer treatment. The FDA awards this classification to therapies addressing rare diseases, providing advantages such as periods of market exclusivity and various developmental incentives.
Beyond pancreatic cancer, Can-Fite is also investigating namodenoson for advanced liver cancer applications. This compound represents one of the company’s primary pipeline candidates alongside piclidenoson, which the company is developing for psoriasis treatment.
Future scientific conferences will feature more comprehensive survival data presentations from the company. However, specific conference venues and presentation dates have not yet been disclosed.
Company Finances
Can-Fite operates as a clinical-stage biopharmaceutical company. The firm has not yet produced significant product sales revenue and continues to operate in the red. Revenue figures have contracted at a -41.5% rate across the preceding three-year period.
The company’s operating margin registers at -1,595%, while its Altman Z-Score stands at -26.39, an indicator typically associated with financial stress. Institutional investors hold just 3.49% of outstanding shares.
CANF currently trades at a market capitalization of roughly $6.24 million, placing it firmly in micro-cap territory. Following the trial announcement on March 4, shares experienced a single-day surge of +107.80%.
The latest analyst recommendation for CANF is rated as Hold, accompanied by a $0.20 price target. This target presents a notable contrast to the stock’s dramatic upward movement following the positive trial announcement.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
